Objective  To observe the efficacy of intravitreal injection of conbercept (IVC) combined with suprachoroidal injection of triamcinolone acetonide (SCTA) in the treatment of macular edema secondary to retinal vein occlusion (RVO-ME). Methods A prospective clinical study. Twenty-eight eyes of 28 patients with RVO-ME diagnosed at Tianjin Eye Hospital from January to October 2025 were included in the study. Among them, there were 13 eyes of 13 males and 15 eyes of 15 females; all were monocular. The age was (62.9±9.4) years. All affected eyes underwent best corrected visual acuity (BCVA), eye pressure, optical coherence tomography (OCT), and fundus fluorescein angiography (FFA) examinations. BCVA was examined using the international standard visual acuity chart, and the results were converted to logarithm of the minimum angle of resolution visual acuity for statistical analysis. The OCT instrument was used to measure central macular thickness (CMT) and subfoveal choroidal thickness (SFCT). The patients were randomly divided into an experimental group and a control group using a random number table, with 14 eyes in each group. The control group received IVC 0.05 ml (containing conbercept 0.5 mg); the experimental group received suprachoroidal injection of triamcinolone acetonide 0.1 ml (containing triamcinolone acetonide 4.0 mg) combined with IVC, with the same dose as the control group. Relevant examinations were performed using the same equipment and methods as before treatment at 1-3 and 6 months after treatment. Changes in BCVA, eye pressure, CMT, and SFCT were compared between the two groups; the occurrence of complications such as cataract progression, endophthalmitis, vitreous hemorrhage, and retinal detachment was also observed. Intergroup comparisons were performed using the two independent samples t test, and intragroup comparisons before and after treatment were performed using the paired t test. Results Compared with baseline, BCVA was significantly improved, and CMT and SFCT were significantly decreased in both the control and experimental groups at 1, 2, 3, and 6 months after treatment, with statistically significant differences (P＜0.05). Intergroup comparison showed that at 1 month after treatment, the improvement in BCVA (Z=?2.262) and the reduction in CMT (Z=?2.482) in the experimental group were significantly better than those in the control group, with statistically significant differences (P＜0.05); at 2 months after treatment, the reduction in SFCT in the experimental group was significantly better than that in the control group, with a statistically significant difference (Z=?1.977, P＜0.05). At 3 and 6 months after treatment, there were no statistically significant differences in the increase in BCVA and the decreases in CMT and SFCT between the two groups (P＞0.05). The number of injections in the control group was (3.36±0.63) times, which was significantly higher than that in the experimental group, with a statistically significant difference (t=2.110, P＜0.05). At 1 month after treatment, one eye in the experimental group showed a transient mild increase in eye pressure; no significant cataract progression was observed in any affected eye, and no complications such as vitreous hemorrhage, retinal detachment, or endophthalmitis occurred. Conclusion IVC combined with SCTA can rapidly improve visual acuity and anatomical structure in eyes with RVO-ME, reduce the need for anti-vascular endothelial growth factor injections, and has no significant adverse reactions.

Citation： Li Xiaoli, Wang Xia, Ren Liyu, Wu Bin, Han Quanhong, Wang Ying. Clinical observation of intravitreal Conbercept combined with suprachoroidal triamcinolone acetonide for macular edema secondary to retinal vein occlusion. Chinese Journal of Ocular Fundus Diseases, 2026, 42(8): 661-667. doi: 10.3760/cma.j.cn511434-20251124-00520 Copy

Copyright ? the editorial department of Chinese Journal of Ocular Fundus Diseases of West China Medical Publisher. All rights reserved